Lapatinib ditosylate

Lapatinib ditosylate 구조식 이미지
카스 번호:
388082-78-8
상품명:
Lapatinib ditosylate
동의어(영문):
Lapatinib ditosylate Monohydrate;Lapatinib tosilate;Lapatinib ditosylate hydrate;Lapatinb;GW2016 ditosylate;GW-572016;GW572016;(E)-Ferulic acid-d;lapatinib(GW572016);Lapatinib Ditosilate;Lapatinib ditosylate
CBNumber:
CB2966227
분자식:
C41H40ClFN4O11S3
포뮬러 무게:
925.46
MOL 파일:
388082-78-8.mol

Lapatinib ditosylate 속성

녹는점
>200oC (dec.)
저장 조건
under inert gas (nitrogen or Argon) at 2-8°C
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
물리적 상태
단단한 모양
색상
노란색
CAS 데이터베이스
388082-78-8(CAS DataBase Reference)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
그림문자(GHS):
신호 어:
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H413 장기적 영향에 의해 수생생물에 유해의 우려가 있음 수생 환경유해성 물질 - 만성 구분 4
예방조치문구:

Lapatinib ditosylate C화학적 특성, 용도, 생산

용도

Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor.

일반 설명

Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of <0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t1/2=300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.

Lapatinib ditosylate 준비 용품 및 원자재

원자재

준비 용품


Lapatinib ditosylate 공급 업체

글로벌( 351)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Hebei Mojin Biotechnology Co., Ltd
+8613288715578
sales@hbmojin.com China 12470 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 6011 58
Hebei Duling International Trade Co. LTD
+8618712993135
sales01@hbduling.cn China 15734 58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
+86-0531-69954981 +8615666777973
dwyane.wang@boyuanpharm.com China 211 58
hebei hongtan Biotechnology Co., Ltd
+86-86-1913198-3935 +8617331935328
sales03@chemcn.cn China 952 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806
sales@capotchem.com China 29797 60
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497
sales01@cooperate-pharm.com CHINA 1811 55
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21689 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 - 03@
sales03@shyrchem.com CHINA 738 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32686 60

Lapatinib ditosylate 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved